Thursday 16 October, 2025
Objectives: Voriconazole is a broad-spectrum antifungal agent for the treatment of invasive aspergillosis. The aims of this study were to develop…
Read morePoster: Drug/Disease Modelling - Infection
Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration
Thursday 16 October, 2025
Objectives: Voriconazole (VRC) is an antifungal drug used for prophylaxis and therapy of various fungal infections. The main route of…
Read morePopulation pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy
Thursday 16 October, 2025
Objectives: Voriconazole (VRC), a broad-spectrum antifungal drug used to treat invasive fungal infections, shows complex pharmacokinetics and is primarily metabolised by…
Read moreComparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort
Thursday 16 October, 2025
Objectives: The rate of depression in patients with HIV is higher than in the general population with up to 40–60 %…
Read moreInfluence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV.
Thursday 16 October, 2025
Objectives: Antiretroviral treatments (ARTs) have transformed HIV infection from a deadly disease to a chronic condition. People living with HIV…
Read moreInfluence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients.
Thursday 16 October, 2025
Objectives: Artemether-lumefantrine is the most widely recommended first-line treatment for uncomplicated falciparum malaria globally. Considering the substantial geographic overlap of HIV…
Read moreA pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications.
Thursday 16 October, 2025
Objectives: Abacavir given together with other antiretrovirals (ARV) such as efavirenz, lamivudine and lopinavir/ritonavir (4:1) are recommended as a component…
Read moreTB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children
Thursday 16 October, 2025
Objectives: Co-treatment of HIV and tuberculosis in infants and young children is unavoidable in much of Africa, increasing risks for…
Read morePopulation pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute.
Thursday 16 October, 2025
Objectives: Resorbable bone graft substitutes such as calcium sulfate (CaSO4) can be used as carrier material for local antimicrobial therapy…
Read moreEvaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models
Thursday 16 October, 2025
Objectives: There is a wide discrepancy describing the influence of a cardiopulmonary bypass (CPB) on drugs used during surgery (e.g….
Read more